Table 2.
Data on patients at baseline and follow up
| Baseline n = 52 | 6-Week follow-up n = 39 | Statistics baseline follow-up |
|
|---|---|---|---|
| Total vitamin C μmol/L, mean (SD) | 57.4 (±25.9) | 58.2 (±22.7) | t = 0.7, P = .472 |
| PANSS total | 75.6 (±14.4) | 59.9 (±13.5) | t = 8.1, P < .001 |
| Positive | 18.6 (±4,4) | 13.8 (±4.4) | t = 9.4, P < .001 |
| Negative | 19.4 (±5,3) | 16.9 (±16.7) | t = 3.5, P = .001 |
| General | 37.6 (±7.5) | 29.3 (±7.1,) | t = 7.7, P < .001 |
| PSP | 48.3a (±14.2) | 56.9b (±12.5) | t = 4,5, P < .001 |
| CDSS | 8.3 (±3.9) | 4.6 (±4.4) | t = 4.1, P < .001 |
| BMI | 24.9 (±6.6) | 24.2(±6.0) | T = 0.8, P = .408 |
| Aripiprazole dose (mg/d) | 10.3c (2.5-25) | ||
| P-aripiprazole (ng/mL) | 303.3 (±235.9) | ||
| P-aripiprazole and dehydroaripiprazole (ng/mL) | 450.1(±128.8) |
Bold values indicates significant group difference, P < .05.
Abbreviations: BMI, body mass index; CDSS, Calgary Depression Scale for Schizophrenia; PANSS, Positive and Negative Symptom Scale; PSP, Personal and Social Performance scale.
a Consumptions of fruit and vegetables: (multiple times pr. day/daily/less than daily).
b Counting multivitamin and/or vitamin C.
c Median for the whole sample was 69.5 µM.
a: n = 51 b: n = 37 c: n = 34